Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Roelof W. Feenstra is active.

Publication


Featured researches published by Roelof W. Feenstra.


Archive | 2001

Piperazine and piperidine compounds

Roelof W. Feenstra; Cornelis G. Kruse; Martinus Theodorus Maria Tulp; Wilma Kuipers; S.K. Long


Archive | 1999

New piperazine and piperidine compounds

Roelof W. Feenstra; Der Heijden Johannes A. M. Van; Johannes Mos; S.K. Long; Gerben M. Visser; Cornelis G. Kruse; Scharrenburg Gustaaf J M Van; Anne G. Toorop; Gerrit P. Toorop


European Neuropsychopharmacology | 2000

DU 127090: a highly potent, atypical dopamine receptor ligand — a putative potent full spectrum antipsychotic with low EPS potential

B.J. Van Vliet; Jan Mos; J.A.M. Van Der Heijden; Roelof W. Feenstra; Cornelis G. Kruse; S.K. Long


Archive | 2005

Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition

Roelof W. Feenstra; Axel Stoit; Jan-Willem Terpstra; Maria L. Pras-Raves; Andrew C. McCreary; Bernard J. Van Vliet; Mayke B. Hesselink; Cornelis G. Kruse; Gustaaf J. M. Van Scharrenburg


Archive | 2006

N-oxides as prodrugs of piperazine & piperidine derivatives

Theodorus S. M. Koopman; Hendrik J. Koster; Amsterdam Peter H. Van; Roelof W. Feenstra; Marinus Verhage; Andrew C. McCreary; Mayke B. Hesselink; Scharrenburg Gustaaf J M Van


Archive | 2005

2-Substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity

Melle Koch; Jacobus A. J. den Hartog; Gerrit-jan Koomen; Martinus J. Wanner; Roelof W. Feenstra


European Neuropsychopharmacology | 2002

SLV313 is a dopamine D2 receptor antagonist and serotonin 5-HT1A receptor agonist: In vitro and in vivo neuropharmacology

J. Glennon; Andrew C. McCreary; E. Ronken; R. Siarey; Mayke B. Hesselink; Roelof W. Feenstra; B.J. Van Vliet; S.K. Long; Cornelis G. Kruse


European Neuropsychopharmacology | 2000

DU 127090: a highly potent, atypical dopamine receptor ligand — high potency but low efficacy at dopamine D2 receptors in vitro

B.J. Van Vliet; E. Ronken; Martinus T. M. Tulp; Roelof W. Feenstra; Cornelis G. Kruse; S.K. Long


Archive | 1998

Piperazine compounds, their preparation, and methods of using them

Roelof W. Feenstra; Gerben M. Visser; Cornelis G. Kruse; Martinus T. M. Tulp; S.K. Long


Archive | 2006

Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neruotransmission

Benjamin Drukarch; Anton N. M. Schoffelmeer; Roelof W. Feenstra; Marie-Odile Christen; Jean-Louis Burgot; Marylene Chollet; Wouter I. Iwema Bakker; Bernard J. Van Vliet; Martinus T. M. Tulp

Researchain Logo
Decentralizing Knowledge